No abstract

OBJECTIVE -The aim of the study was to assess the prevalence of diabetes and depression and their associations with quality of life using a representative population sample.RESEARCH DESIGN AND METHODS -The study consisted of a representative population sample of individuals aged Ն15 years living in South Australia comprising 3,010 personal interviews conducted by trained health interviewers. The prevalence of depression in those suffering doctor-diagnosed diabetes and comparative effects of diabetic status and depression on quality-of-life dimensions were measured.RESULTS -The prevalence of depression in the diabetic population was 24% compared with 17% in the nondiabetic population. Those with diabetes and depression experienced an impact with a large effect size on every dimension of the Short Form Health-Related Quality-of-Life Questionnaire (SF-36) as compared with those who suffered diabetes and who were not depressed. A supplementary analysis comparing both depressed diabetic and depressed nondiabetic groups showed there were statistically significant differences in the quality-of-life effects between the two depressed populations in the physical and mental component summaries of the SF-36.CONCLUSIONS -Depression for those with diabetes is an important comorbidity that requires careful management because of its severe impact on quality of life.

No abstract

The metabolic and cardiovascular side‐effects of intravenous infusions of therapeutic doses of beta 2‐adrenoceptor agonists salbutamol and rimiterol have been determined in four healthy male subjects. There were dose‐related increases in plasma glucose, renin activity, serum insulin and heart rate, and significant hyperlactataemia and ketonaemia. There were dose‐related decreases in plasma potassium, phosphate and corticosteroids and significant hypocalcaemia and hypomagnesaemia. The effects of equivalent molar amounts of salbutamol and rimiterol were similar. Whichever drug is used, special care is required with patients who may have abnormal glucose tolerance, potassium depletion, or be predisposed to lactic acidosis. Rimiterol may be preferable for infusion because of its short plasma half‐life.

No abstract